TheraRadar
← Back
Data updated: Jun 28, 2026

APPLIED ANAL

Generics
Ophthalmology Execution: Needs Improvement

APPLIED ANAL is a generic drug manufacturer focused on Ophthalmology.

1997
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

APPLIED ANAL's Key Drugs

APPLIED ANAL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

APPLIED ANAL's Recent FDA Approvals

New NDA/BLA approvals for APPLIED ANAL over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

APPLIED ANAL's Therapeutic Areas

APPLIED ANAL's approved drugs and pipeline span 1 therapeutic area, led by Ophthalmology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Ophthalmology 100%
1 drugs

APPLIED ANAL's Top Competitors

APPLIED ANAL's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and OTSUKA ICU MEDCL. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Ophthalmology
AbbVie big-pharma
Ophthalmology
OTSUKA ICU MEDCL specialty
Ophthalmology
Bayer big-pharma
Ophthalmology
Roche big-pharma
Ophthalmology

APPLIED ANAL Pipeline Snapshot

Active clinical trials for APPLIED ANAL across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Ophthalmology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/2 completed
  • • Speed: N/A months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges